Vol 14, No 2 (2011)
Research paper
Published online: 2012-01-04
Comparison of receptor affinity of natSc-DOTA-TATE versus natGa-DOTA-TATE
Nucl. Med. Rev 2011;14(2):85-89.
Abstract
BACKGROUND: 44Sc as a positron emitter can be an interesting
alternative to 68Ga (T½ = 67.71 min) due to its longer half-life
(T½ = 3.97 h). Moreover, the b– emitter 47Sc can be used for
therapy when attached to the same biomolecule vectors.
DOTA as a chelating agent has been proven suitable for the
radiolabelling of peptides recognising tumour cell receptors
in vivo with M3+ radiometals. DOTA-derivatized peptides have
been successfully labelled with 90Y and 177Lu for therapy,
and with 68Ga for PET imaging. However, published data on
44Sc-labelled DOTA-biomolecules as potential PET radiotracers
are still very limited. The aim of this study was to compare
the affinity of natGa- and natSc-labelled DOTA-TATE to
somatostatin receptors subtype 2 expressed in rat pancreatic
cancer cell line AR42J.
MATERIAL AND METHODS: The cold complexes of DOTA-TATE with natGa and natSc were synthesized and identified by HPLC and MS analysis and evaluated in vitro for competitive binding to cancer cell line AR42J expressing somatostatin receptors subtype 2 (sstr2).
RESULTS: The IC50 values calculated from the displacement curve of {125I-Tyr11}-SST-14 were: 0.20 ± 0.18, 0.70 ± 0.20, 0.64 ± 0.22 and 0.67 ± 0.12 for natGa-DOTA-TATE, natSc-DOTA-TATE, DOTA-TATE, and {Tyr11}-SST-14 complexes, respectively, with the affinity lowering in the decreasing order: natGa-DOTA-TATE > DOTA-TATE > Tyr11-SST-14 > natSc-DOTA-TATE.
CONCLUSIONS: The binding affinity of natGa-DOTA-TATE appeared higher than that of natSc-DOTA-TATE. Further in vitro and in vivo studies are needed to verify the influence of the chelated metal on the affinity and uptake of the respective radiolabelled compounds. This information might be crucial when the in vivo applications of peptides labelled with 68Ga and 44Sc for PET, as well as the use of 47Sc for radiotherapy are considered.
Nuclear Med Rev 2011; 14, 2: 85–89
MATERIAL AND METHODS: The cold complexes of DOTA-TATE with natGa and natSc were synthesized and identified by HPLC and MS analysis and evaluated in vitro for competitive binding to cancer cell line AR42J expressing somatostatin receptors subtype 2 (sstr2).
RESULTS: The IC50 values calculated from the displacement curve of {125I-Tyr11}-SST-14 were: 0.20 ± 0.18, 0.70 ± 0.20, 0.64 ± 0.22 and 0.67 ± 0.12 for natGa-DOTA-TATE, natSc-DOTA-TATE, DOTA-TATE, and {Tyr11}-SST-14 complexes, respectively, with the affinity lowering in the decreasing order: natGa-DOTA-TATE > DOTA-TATE > Tyr11-SST-14 > natSc-DOTA-TATE.
CONCLUSIONS: The binding affinity of natGa-DOTA-TATE appeared higher than that of natSc-DOTA-TATE. Further in vitro and in vivo studies are needed to verify the influence of the chelated metal on the affinity and uptake of the respective radiolabelled compounds. This information might be crucial when the in vivo applications of peptides labelled with 68Ga and 44Sc for PET, as well as the use of 47Sc for radiotherapy are considered.
Nuclear Med Rev 2011; 14, 2: 85–89
Keywords: scandium-44gallium-68PET tracersreceptor affinityDOTA-derivatised peptides